Sanofi To Invest $1.05 Bln For New Insulin Production Base In China
LIKE.TG 成立于2020年，总部位于马来西亚，是首家汇集全球互联网产品，提供一站式软件产品解决方案的综合性品牌。唯一官方网站：www.like.tg
(RTTNews) - French drug major Sanofi plans to invest around 1 billion euros or about $1.05 billion to build a new insulin manufacturing base in Beijing, China, reports said.
The move represents Sanofi's single largest investment in China so far, where it has been present for more than 40 years. The investment will boost the manufacturing of insulin to help diabetic patients in the region and enhance the company's supply-chain resilience.
The new site, located in an economic development zone in Yizhuang, will be Sanofi's second production base in Beijing and its fourth in the country.
Sanofi signed a memorandum of cooperation with the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Economic-Technological Development Area or BDA Administrative Committee regarding the investment.
According to Sanofi Chief Executive Paul Hudson, the new production base will feature advanced automated production technologies, cutting-edge digital integrated management systems and sustainable environmental standards.
Medical journal the Lancet reportedly pointed that China now has the largest number of diabetes patients worldwide.
现在关注【LIKE.TG出海指南频道】、【LIKE.TG大客户服务频道】,即可免费领取【WhatsApp、LINE、Telegram、Twitter、ZALO云控】等获客工具试用、【住宅IP、号段筛选】等免费资源，机会难得，快来解锁更多资源，助力您的业务飞速成长！点击【联系客服】
本文由LIKE.TG编辑部转载自互联网并编辑，如有侵权影响，请联系官方客服，将为您妥善处理。
This article is republished from public internet and edited by the LIKE.TG editorial department. If there is any infringement, please contact our official customer service for proper handling.
Server deployment全球论坛人工智能论坛全球峰会发展论坛战略论坛开放论坛程序员论坛互联网峰会科技峰会
